Aldosterone and mineralocorticoid receptors: A personal reflection

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 146-150

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Aldosterone; Mineralocorticoid; Primary aldosteronism; Steroid receptors

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE INHIBITOR; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXYGENASE INHIBITOR; PLACEBO; PROGESTERONE RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ALDOSTERONE RELEASE; DRUG RESPONSE; GYNECOMASTIA; HEART FAILURE; HISTORY OF MEDICINE; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; NONHUMAN; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ALDOSTERONE; ANIMALS; CONCEPT FORMATION; ENDOCRINOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RECEPTORS, MINERALOCORTICOID; THINKING;

EID: 84856347698     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.11.026     Document Type: Review

References (23)

1. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
2. Auchus R.J. Primary aldosteronism and a Texas two-step. Rev. Endocr. Metab. Disord. 2001, 12:37-42.
3. Calhoun D.A. Low dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J. Clin. Hypertens. (Greenwich) 2007, 9:19-24.
4. + channel mutations in adrenal aldosterone producing adenomas and hereditary hypertension. Science 2011, 331:768-772.
5. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989.
6. Epstein M., Willliams G.H., Weinberger M., Lewin B., Krause S., Mukherjee R., Patni R., Beckerman B. Selective aldosterone blockade with eplerenone reduced albumin uria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2006, 1:940-951.
7. Funder J.W. The non genomic actions of aldosterone. Endocrinol. Rev. 2005, 26:313-321.
8. Funder J.W., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264-5268.
9. Funder J.W., Pearce P., Smith R., Smith A.I. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
10. Gomez-Sanchez E.P., Ahmad N., Romero D.G., Gomez-Sanchez C.E. Origin of aldosterone in the rat heart. Endocrinology 2004, 145:4796-4802.
11. Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., Chorazyczewski J., Feldman R.D. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011, 57:442-451.
12. Guder G., Bauersachs J., Frantz S., Weismann D., Allolio B., Erti G., Angermann C.E., Störk S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circ. 2007, 115:1754-1761.
13. Kassahn K.S., Ragan M.A., Funder J.W. Mineralocorticoid receptors: evolutionary and pathophysiological considerations. Endocrinology 2011, 152:1883-1890.
14. Krozowski Z.S., Funder J.W. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. USA 1983, 80:6056-6060.
15. Levy D., Rocha R., Funder J.W. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 2004, 89:2736-2740.
16. Mackenzie, S.M., Connell, J.M., Davies, E., 2011. Non-adrenal synthesis of aldosterone: a reality check. Mol. Cell. Endocrinol. July 13 Epub ahead of print.
17. Mihailidou A.S., Loan, Le T.Y., Mardini M., Funder J.W. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Endocrinology 2009, 54:1306-1312.
18. Milliez P., Girerd X., Plouin P.-F., Blacher J., Safar M.E., Mourad J.-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005, 45:1243-1248.
19. Pearce D. SGK-1 regulation of epithelial sodium transport. Cell. Physiol. Biochem. 2003, 13:13-20.
20. Qin W., Rudolph A., Bond B., Rocha R., Blomme E., Goeliner J., Funder J.W., McMahon E.G. A transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 2003, 93:69-76.
21. Sechi L.A., Colussi G., Di Fabio A., Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am. J. Hypertens. 2010, 12:1253-1260.
22. Stowasser M., Sharman J., Leano R., Gordon R.D., Ward G., Cowley D., Marwick T.H. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 2005, 90:5070-5076.
23. Tait S.A., Tait J.F., Coghlan J.P. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol. Cell. Endocrinol. 2004, 217:1-21.